Argenx Stops Phase 3 Trial for Thyroid Eye Disease Treatment

01:22 AM EST, 12/15/2025 (MT Newswires) -- Argenx (ARGX.BR) decided to stop the phase 3 UplighTED trials for efgartigimod subcutaneous as a proposed treatment for adults with moderate to severe thyroid eye disease. Heeding the advice of an independent data monitoring committee, the immunology company stopped the trials for futility, according to a Monday release. The data showed a favorable safety and tolerability profile for the treatment, with no new safety signals identified. Argenx still intends to share data from the studies at a future medical meeting.